Prognostic factors for cure following treatment of onychomycosis

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 6, 2010, Pages 679-684

  Sigurgeirsson, B ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Onychomycosis; Prognostic factors; Therapy

Indexed keywords

TERBINAFINE; ANTIFUNGAL AGENT; NAPHTHALENE DERIVATIVE;

ADULT; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYCOLOGY; ONYCHOMYCOSIS; OUTPATIENT DEPARTMENT; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; ADOLESCENT; AGED; DOSE RESPONSE; FOOT DERMATOSES; MIDDLE AGED; ORAL DRUG ADMINISTRATION; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOT DERMATOSES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NAPHTHALENES; ONYCHOMYCOSIS; PILOT PROJECTS; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952128384     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03487.x     Document Type: Article

References (19)

1. Gupta AK, Jain HC, Lynde CW et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. J Am Acad Dermatol 2000 43 : 244 248.
2. Elewski BE, Leyden J, Rinaldi MG et al. Office practice-based confirmation of onychomycosis: a US nationwide prospective survey. Arch Intern Med 2002 162 : 2133 2138.
3. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992 126 (Suppl 39 23 27.
4. Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995 133 : 699 703.
5. Sigurgeirsson B, Steingrimsson O, Sveinsdottir S. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 2002 82 : 467 469.
6. Niewerth M, Korting HC. Management of onychomycoses. Drugs 1999 58 : 283 296.
7. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 1999 318 : 1031 1035.
8. Sigurgeirsson B, Olafsson JH, Steinsson JB et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002 138 : 353 357.
9. Sigurgeirsson B, Elewski BE, Rich PA et al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat 2006 17 : 38 44.
10. Sommer S, Sheehan-Dare RA, Goodfield MJ et al. Prediction of outcome in the treatment of onychomycosis. Clin Exp Dermatol 2003 28 : 425 428.
11. Sigurgeirsson B, Paul C, Curran D et al. Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. Br J Dermatol 2002 147 : 1241 1243.
12. Gupta AK, Konnikov N, Lynde CW et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. Eur J Dermatol 1999 9 : 633 638.
13. Geyer AS, Onumah N, Uyttendaele H et al. Modulation of linear nail growth to treat diseases of the nail. J Am Acad Dermatol 2004 50 : 229 234.
14. Yu HJ, Kwon HM, Oh DH et al. Is slow nail growth a risk factor for onychomycosis? Clin Exp Dermatol 2004 29 : 415 418.
15. Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol 1996 76 : 82 83.
16. Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003 149 (Suppl 65 5 9.
17. Roberts DT, Evans EG. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998 138 : 189 190.
18. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol 2001 145 (Suppl 60 15 19.
19. Levy LA. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 1997 87 : 546 550.